Basilea Pharmaceutica (XSWX:BSLN) Tariff Resilience Score: 6/10 (As of Jul. 06, 2026)


XSWX:BSLN Basilea Pharmaceutica Ltd XSWX:BSLN
61 GF Score
Price CHF54.30
GF Value CHF57.56
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Basilea Pharmaceutica Tariff Resilience Score?

Basilea Pharmaceutica XSWX:BSLN +2.26% 61 Tariff Resilience Score is 6 as of Jul. 06, 2026. GuruFocus rates XSWX:BSLN with a GF Score™ of 61/100 and a GF Value™ of CHF57.56 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,369 Biotechnology companies, Basilea Pharmaceutica ranks better than 75.89% on this metric.

Basilea Pharmaceutica has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Basilea Pharmaceutica has Basilea faces moderate tariff risks due to reliance on global supply chains for pharmaceutical ingredients. However, its focus on niche markets and potential for alternative sourcing provide some mitigation against tariff impacts.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Basilea Pharmaceutica might have Average Resilient.

Basilea Pharmaceutica  (XSWX:BSLN) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Basilea Pharmaceutica Tariff Resilience Score Related Terms

XSWX:BSLN vs VRTX, REGN, ALNY: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Basilea Pharmaceutica's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Basilea Pharmaceutica Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Basilea Pharmaceutica's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Basilea Pharmaceutica's Tariff Resilience Score falls into.


XSWX:BSLN
61GF Score
Basilea Pharmaceutica Ltd XSWX:BSLN
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Basilea Pharmaceutica (XSWX:BSLN) has a Tariff Resilience Score of 6 as of Jul. 06, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Basilea Pharmaceutica ranks #330 out of 1369 companies in the Biotechnology industry, placing it in the top 24.1%.
Is Basilea Pharmaceutica's Tariff Resilience Score too high?
Basilea Pharmaceutica's current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. Basilea Pharmaceutica's value of 6 is 50% above this industry median. Based on the distribution chart, Basilea Pharmaceutica ranks #330 out of 1369 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Basilea Pharmaceutica has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Basilea Pharmaceutica's Tariff Resilience Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Basilea Pharmaceutica ranks #330 out of 1369 companies for Tariff Resilience Score. This places Basilea Pharmaceutica in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Basilea Pharmaceutica's value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,369 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Basilea Pharmaceutica's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Basilea Pharmaceutica's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basilea Pharmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Basilea Pharmaceutica (XSWX:BSLN) is currently considered Fairly Valued. The stock's GF Value™ is CHF57.56, compared to a current price of CHF54.30 — trading 5.7% below its estimated fair value. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Basilea Pharmaceutica's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Basilea Pharmaceutica (XSWX:BSLN), the current Tariff Resilience Score is 6 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Basilea Pharmaceutica (XSWX:BSLN) Overvalued in 2026?

Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be undervalued. The current stock price of CHF54.30 is trading 5.7% below its estimated GF Value™ of CHF57.56. GuruFocus considers Basilea Pharmaceutica to be Fairly Valued.

Key valuation signals for XSWX:BSLN:

  • Tariff Resilience Score: 6
  • GF Value™: CHF57.56 vs. price of CHF54.30 (5.7% below fair value)
  • GF Score™: 61/100 with 4 warning signs
  • Industry Position: 50% above the Biotechnology median (#330 of 1369)

No single metric tells the full story. See the XSWX:BSLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Basilea Pharmaceutica Business Description

Address Hegenheimermattweg 167b, Allschwil, CHE, 4123
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
61GF Score

Get the complete analysis for XSWX:BSLN

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF54.30
Price
CHF57.56
GF Value